[124I]-girentuximab PET/CT shows considerable promise in the diagnostic evaluation of ccRCC due to its high specificity for carbonic anhydrase IX (CAIX), which is highly expressed in the majority of ccRCC cases [38]. This evidence concerns the gene CA9 and nonpapillary renal cell carcinoma.